| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -18,581 | -17,433 | -55,348 | NaN |
| Depreciation | 88 | 93 | 90 | 223 |
| Amortization of intangible assets | 167 | 166 | 166 | 333 |
| Stock-based compensation | 1,912 | 4,970 | 5,617 | 10,870 |
| Non-cash lease expense | 308 | 306 | 847 | NaN |
| Write-off of deferred issuance costs | 281 | NaN | NaN | NaN |
| Loss on disposal of fixed assets | NaN | 0 | NaN | NaN |
| Other | -62 | NaN | NaN | NaN |
| Accounts receivable | -55 | 259 | 15 | NaN |
| Inventory | 70 | 79 | 57 | NaN |
| Prepaid expenses and other current assets | 129 | 374 | 538 | NaN |
| Other receivables | NaN | NaN | 14 | NaN |
| Other non-current assets | -3 | -14 | 28 | NaN |
| Accounts payable | -148 | -186 | 1,318 | NaN |
| Accrued liabilities | 1,832 | -1,627 | -1,823 | NaN |
| Lease liabilities, net | -375 | -360 | -1,008 | NaN |
| Net cash used in operating activities | -14,595 | -14,755 | -13,039 | -26,328 |
| Purchases of property and equipment | 33 | 105 | 62 | 148 |
| Purchases of intangible assets | NaN | 0 | 0 | 20 |
| Net cash used in investing activities | -33 | -105 | -62 | -168 |
| Proceeds from issuance of common stock under employee stock purchase plan | 465 | -7 | 241 | 352 |
| Proceeds from issuance of common stock and warrants in relation to rights offering, net of issuance costs | NaN | 0 | 0 | NaN |
| Proceeds from exercises of warrants, net of issuance costs | 130 | 1 | 17 | 14,063 |
| Proceeds from exercises of stock options | 1,674 | 387 | 1,708 | 392 |
| Payment of deferred issuance costs in relation to registration statements | 57 | 0 | 0 | 0 |
| Net cash provided by financing activities | 2,212 | 381 | 1,966 | 14,807 |
| Net (decrease) increase in cash and cash equivalents | -12,416 | -14,479 | -11,135 | -11,689 |
| Cash and cash equivalents at beginning of period | 95,214 | NaN | 118,038 | NaN |
| Cash and cash equivalents at end of period | 68,319 | NaN | 95,214 | NaN |
PULSE BIOSCIENCES, INC. (PLSE)
PULSE BIOSCIENCES, INC. (PLSE)